New Trial Shows BENEFIT Of J&J/Auris’ Monarch Bronchoscopy Platform
New published results demonstrate J&J/Auris’ robotic is safe and effective at diagnosing peripheral pulmonary lesions.
You may also be interested in...
Optellum’s Virtual Nodule Clinic artificial intelligence technology will be part of Johnson & Johnson’s Lung Cancer Initiative, an ongoing research program intended to improve lung cancer survival rates through early intervention and prevention.
J&J said its Ottava robotic platform has six robotic arms, “zero footprint,” and can be used for various procedures.
Johnson & Johnson will acquire robotic startup Auris Health for $3.4bn in cash, plus milestones payments of up to $2.4bn. Auris developed the FDA-cleared Monarch platform, which is expected to rival Intuitive Surgical's robotic-assisted bronchoscope device, Ion, awaiting FDA clearance.